Will smaller biotech companies challenge or replace the current cohort of Big Pharma?

Will smaller biotech companies challenge or replace the current cohort of Big Pharma?

The Financial Times released an article on 14 August 2020 highlighting the significant increase in healthcare IPOs of companies that are working towards a Covid-19 vaccine. According to Martin Steinbach, Head of EY’s IPO and listing services EMEIA, “2020’s initial...

Continue reading →